Aprea Therapeutics Shares Slide After Early APR-1051 Phase 1 Data Draws Tepid Market Response
Aprea Therapeutics' stock plunged after the company published early results from its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor. The data include one unconfirmed partial response in an endometrial cancer patient and several instances of stable disease with modest tumor reductions across lower dose cohorts. Enrollment is underway in the…